PCL201H1 Lecture Notes - Lecture 5: Intrathecal Administration, Facilitated Diffusion, Saccharin
11 Jan 2018
School
Department
Course
Professor
Document Summary
Therapeutic failure: anti-infectious disease agents, pgp polymorphisms, anionic/cationic transporters, cancers, abc transporters unregulated and over expressed in tumours. Improving ef cacy and safety: increase distribution (statins delivered to targets, removed drugs from locations (placenta, digoxin) Route: method by which drug is introduced to body: affects absorption, bioavailability, effect, speed of onset, duration and toxicity, unless topical, must be absorbed into systemic circulation, consider, physiochemical, target site, reach, dose, onset and duration, bioavailability, bioactivation, Adr, compliance: enteral (through gi) or parenteral (no gi, injections, local (at site of admin) or systemic (enters circulation) Bioavailability: how much reaches systemic, route dependent (iv is 100%, first pass: absorbed from gi and delivered to liver via portal vein, can be metabolized before reaching systemic. Topical: local application to body, local, small doses, no rst pass, low side effects, rapid onset, impractical, ointments, creams, drops, sprays, body cavity injections, intrathecal injections.
